Crucible brings together a highly collaborative team of R&D experts and biotech entrepreneurs. With deep expertise across research, development, and commercialisation, we are dedicated to advancing innovative RNA-based therapies to transform patient outcomes. Our work originates from the Sheffield Institute for Translational Neuroscience (SITraN) and the Sheffield NIHR Biomedical Research Centre (BRC) at the University of Sheffield – both internationally recognised institutes in neurodegenerative disease research.
Chief Scientific Officer, Co-Founder & Director
Chief Scientific Officer & Scientific Founder
Chief Medical Advisor & Co-Founder
Professor Cold Spring Harbor Laboratory, Co-founder of Stoke Therapeutics
The company’s investors are Argobio Studio and Northern Gritstone, who provide financing and operational leadership.
Argobio, a start-up studio based in Paris, France, specialises in transforming cutting-edge innovations into groundbreaking biotech companies.
The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Series A financing.
With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development.
Northern Gritstone is a groundbreaking investment company, which is dedicated to supporting the commercialisation of academic spinouts and IP-rich businesses based in the North of England.
Launched in July 2021 by the Universities of Leeds, Manchester and Sheffield, it was founded with the philosophy of Profit with Purpose, combining strong returns for investors with wider positive, societal and economic impact, including supporting Levelling Up and high-skilled job creation in the North of England.
The company is deploying more than £300m of capital, having secured commitments from a broad and diverse base of investors including British Patient Capital, Greater Manchester Pension Fund, West Yorkshire Pension Fund, M&G and Columbia Threadneedle, among others. It is dedicated to financing companies in some of the UK’s fastest growing sectors such as advanced materials, energy, health technology and cognitive computation and has already made 11 investments in some of the UK’s most exciting future science and technology-enabled businesses.
We seek partners with capabilities to accelerate our programs and market access, increase effectiveness, quality and productivity.
